Oncology Perspective

• Key Updates in Early Breast Cancer From SABCS 2024   Key updates from SABCS 2024 in early breast cancer include the COMET study on DCIS recurrence, INSEMA trial on SLNB omission, and OlympiA updates on adjuvant olaparib, shared by Dr Harold Burstein.
  Medscape, January 09, 2025
• Simple Text Reminders Help Increase Vaccine Uptake   Dr Maurie Markman discusses the importance of implementation research to address pragmatic questions.
  Medscape Oncology, January 09, 2025
• Skills Lab: Assessing the Introduction and Methods Sections   Dr Bishal Gyawali discusses tips for reading a phase 3 clinical trial publication, focusing on the introduction and methods sections.
  Medscape Oncology, January 08, 2025
• Making Sense of Mixed Messages on Drinking   Medscape’s Neha Pathak, MD, and George Koob, PhD, Director of the National Institute on Alcohol Abuse and Alcoholism, break down the latest guidance on alcohol intake.
  Medscape Family Medicine, January 07, 2025
• Continuing Melanoma Research: Why, How, What?   Dr Teresa Amaral discusses why it is important to continue speaking about melanoma.
  Medscape Oncology, January 06, 2025
• Conference MDAngle: SABCS 2024 Hormone Receptor (HR)–Positive, HER2-Negative Breast Cancer Drs Armaghani and Henry share SABCS 2024 highlights, including anticipated presentations, quick takeaways, and insights into how new research will affect their patients.
  Medscape, January 02, 2025
• Updates in ER-Positive Breast Cancer From SABCS 2024   Updates in ER+ breast cancer from SABCS 2024 include the EMBER-3 trial of novel oral SERD imlunestrant, PATINA trial results, and updated analysis from TAILORx, as reported by Dr Harold Burstein.
  Medscape, January 02, 2025
• Benefits of Playing Drums: Physical, Mental, and Social   Professor David Kerr discusses the benefits of drumming.
  Medscape Oncology, January 02, 2025
• ASH 2024: Clinical Impact of Promising Treatments for PNH   Dr Ilene Weitz reviews data on novel agents and their efficacy in enhancing quality of life and minimizing breakthrough events.
  Medscape, January 02, 2025
• Key Studies in Acute Lymphoblastic Leukemia From ASH 2024   Highlights in acute lymphoblastic leukemia (ALL) from ASH 2024 include significant results for blinatumomab in pediatric ALL, potential use of asciminib, and frontline use of CAR-T cell therapy.
  Medscape, January 02, 2025
• SABCS 2024: Clinical Impact of Advances in HR+ Breast Cancer   Drs Armaghani and Henry share SABCS 2024 highlights, including anticipated presentations, quick takeaways, and insights into how new research will affect their patients.
  Medscape, January 02, 2025
• Conference MDAngle: ASH 2024 Paroxysmal Nocturnal Hemoglobinuria Dr Ilene Weitz shares ASH 2024 highlights, including anticipated presentations, quick takeaways, and insights into how new research will affect her patients.
  Medscape, January 02, 2025
• Conference MDAngle: ASH 2024 Anemia and Red Blood Cell/Erythropoiesis-Related Disorders   Dr Nadia D. Ali shares ASH 2024 highlights, including anticipated presentations, quick takeaways, and insights into how new research will affect her patients.
  Medscape, December 31, 2024
• ASH 2024: Improving Care in Red Blood Cell Disorders   Dr Nadia Ali shares ASH 2024 highlights, including anticipated presentations, quick takeaways, and insights into the impact of new research in red blood cell disorders.
  Medscape, December 31, 2024
• Key Studies in Chronic Lymphocytic Leukemia From ASH 2024   Practice-changing studies in both frontline CLL and relapsed/refractory disease, presented at ASH 2024, are discussed by Dr Jennifer Woyach.
  Medscape, December 30, 2024
• Paroxysmal Nocturnal Hemoglobinuria Takeaways From ASH 2024   Symptom improvement with novel therapies and better patient-reported outcomes, as well as breakthrough hemolysis control, are among the paroxysmal nocturnal hemoglobinuria highlights from ASH 2024.
  Medscape, December 30, 2024
• Novel Insights in Thrombotic Disorders From ASH 2024   Rilzabrutinib and eltrombopag in immune thrombocytopenia, and the place of oral direct anticoagulation in venous thromboembolism, are among the novel insights in thrombotic disorders from ASH 2024.
  Medscape, December 30, 2024
• Cancer Survivors: A Rising Population With Big Implications   Dr Maurie Markman discusses the implications of a growing population of cancer survivors in the United States.
  Medscape Oncology, December 30, 2024
• DLBCL Highlights From ASH 2024   Dr John Leonard shares key updates on DLBCL at ASH 2024, including long-term POLARIX trial data, ctDNA insights, and real-world results for polatuzumab, liso-cel, and bispecifics after CAR-T failure.
  Medscape, December 30, 2024
• Chronic Myeloid Leukemia Highlights From ASH 2024   Highlights in chronic myeloid leukemia from ASH 2024 include data on efficacy of asciminib over TKIs, benefit from the third-generation TKI olverembatinib, and importance of molecular monitoring.
  Medscape, December 30, 2024